Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience
Michalis P. Migkos, Evripidis Kaltsonoudis, Eleftherios Pelechas, Vassiliki Drossou, Panagiota G. Karagianni, A Kavvadias, Paraskevi V. Voulgari, Alexandros A. Drosos
Topics & Concepts
MedicineRheumatologyRheumatic diseaseCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakInternal medicineDiseaseBiological drugsSingle CenterIntensive care medicinePhysical therapyVirologyInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesIntramuscular injections and effectsRheumatoid Arthritis Research and Therapies